Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production.

Abstract

Most types of cancer are difficult to eradicate and some, like liver carcinomas, are almost always fatal. Significantly, we report here that direct intraarterial delivery of 3-bromopyruvate (3-BrPA), a potent inhibitorof cell ATP production, to liver-implanted rabbit tumors, inflicts a rapid, lethal blow to most cancer cells therein. Moreover, systemic delivery of 3-BrPA suppresses "metastatic" tumors that arise in the lungs. In both cases, there is no apparent harm to other organs or to the animals. Thus, intraarterial delivery of agents like 3-BrPA directly to the site of the primary tumor, followed by systemic delivery only when necessary, may represent a powerful new strategy for arresting the growth of liver and other cancers while minimizing toxic side effects.

• Authors: Jean-Francois H Geschwind, Young H Ko, Michael S Torbenson, Carolyn Magee, Peter L Pedersen
• Journal: Cancer research (Cancer Res) Vol. 62 Issue 14 Pg. 3909-13 (Jul 15 2002) ISSN: 0008-5472 [Print] United States
• PMID: 12124317 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Pyruvates
• bromopyruvate
• Adenosine Triphosphate

Topics

• Adenosine Triphosphate (antagonists & inhibitors, biosynthesis)
• Animals
• Antineoplastic Agents (administration & dosage)
• Cell Division (drug effects)
• Cell Survival (drug effects)
• Embolization, Therapeutic
• Injections, Intra-Arterial
• Liver Neoplasms, Experimental (drug therapy, metabolism, pathology, therapy)
• Lung Neoplasms (drug therapy, pathology, secondary)
• Neoplasm Transplantation
• Pyruvates (administration & dosage, adverse effects)
• Rabbits